Company profile
NORTHWEST BIOTHERAPEUTICS INC CIK 1072379
Ticker
NWBO (OTC)
Industry
Pharmaceutical Preparations
Headquarters
Bethesda, MD 20814
Fiscal year end
2025 (FY)
Key Financials
Revenue
$1.38M
Net income
-$60.16M
Total assets
$81.29M
Total liabilities
$128.86M
Stockholders' equity
-$60.28M
Cash & equivalents
$3.04M
Operating income
-$59.91M
Operating cash flow
-$44.76M
Capital expenditures
$1.50M
Fiscal year 2025, via 10-K filed 2026-04-15. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.
Financial Performance
Operating margin
-4,347.9%
Net margin
-4,365.9%
Free cash flow
-$46.27M
Free cash flow margin
-3,357.5%
Liabilities / assets
158.5%
Equity / assets
-74.2%
CapEx / revenue
109.1%
Operating cash flow / net income
0.74×
Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.
Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025
$1.38M
-$60.16M
$81.29M
$128.86M
-$60.28M
2024
$1.38M
-$83.78M
$26.73M
$105.71M
-$94.49M
2023
$1.93M
-$62.60M
$27.87M
$74.92M
-$65.77M
2022
$1.68M
-$105.03M
$31.32M
$136.37M
-$128.10M
2021
$1.01M
$179.13M
$40.16M
$164.15M
-$123.99M
Company Details
SIC code
2834
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 10-Q
2026-08-14
Financials filed via
Form 10-K
filed 2026-04-15
"Most recent SEC filing" may differ from the filing used for the financial figures above.
Location
Bethesda, MD 20814
Data & Methodology
SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:32 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.